Andrew D. Krahn, MD, FHRS discusses this article with guests Jason D. Roberts, MD and Julia Cadrin-Tourigny, MD, PhD, CCDS. Clinical guidelines recommend regular screening for arrhythmogenic right ventricular cardiomyopathy (ARVC) to monitor at-risk relatives, resulting in a significant burden on clinical resources. Prioritizing relatives on their probability of developing definite ARVC may provide more efficient patient care.

https://www.hrsonline.org/education/TheLead

Host Disclosure(s): A. Krahn: Honoraria/Speaking/Consulting Fee: Medtronic, Inc

Contributor Disclosure(s): J. Roberts: Honoraria/Speaking/Consulting Fee: Ionis PharmaceuticalsJ. Cadrin-Tourigny: Honoraria/Speaking/Consulting Fee: BMS/Pfizer Alliance, Bayer Healthcare Pharmaceuticals, Tenaya Therapeutics